Precision BioSciences ownership filing: Empery Asset Management and Ryan M. Lane report collective beneficial ownership of 1,968,879 shares of Precision BioSciences common stock, representing 7.63% of the class based on 25,803,199 shares outstanding as of March 25, 2026. The cover page shows Empery and Mr. Lane hold shared voting and dispositive power over those shares. The filing is an amended Schedule 13G/A that attributes the position to the Investment Manager and to Mr. Lane in his capacity as managing member; each party disclaims direct beneficial ownership of shares held by another.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed: Empery/ Lane hold 7.63% of shares.
This Schedule 13G/A reports 1,968,879 shares tied to Empery Funds under the Investment Manager's discretion, representing 7.63% of the outstanding common stock as of March 25, 2026. The filing classifies the position under investment-manager attribution rather than direct personal ownership.
Key dependencies include the Preliminary Proxy Statement source for the 25,803,199 shares outstanding anchor; subsequent filings could change the percentage if the share count moves. Cashflow treatment and any planned transactions are not described in the excerpt.
Key Figures
Shares beneficially owned:1,968,879 sharesPercent of class:7.63%Shares outstanding:25,803,199 shares
3 metrics
Shares beneficially owned1,968,879 sharesreported beneficial ownership by Empery/Lane
Percent of class7.63%calculated using shares outstanding as of March 25, 2026
Shares outstanding25,803,199 sharesas of March 25, 2026 per Preliminary Proxy Statement
Key Terms
Schedule 13G/A, beneficially owned, shared dispositive power
3 terms
Schedule 13G/Aregulatory
"Amendment No. 1; reporting beneficial ownership of >5%"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially ownedfinancial
"Amount beneficially owned: The information required by Item 4(a) is set forth"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
What stake does Empery Asset Management hold in Precision BioSciences (DTIL)?
Empery Asset Management and related Reporting Persons beneficially hold 1,968,879 shares, equal to 7.63% of the class. This percentage uses an outstanding share base of 25,803,199 shares as of March 25, 2026.
Who is Ryan M. Lane in the Schedule 13G/A for Precision BioSciences?
Ryan M. Lane is the Reporting Individual and the managing member connected to the Investment Manager. He is reported with shared voting and dispositive power over 1,968,879 shares, reflecting the Empery Funds' position.
Does the filing indicate Empery or Lane will sell or buy shares?
No. The amendment is an ownership disclosure (Schedule 13G/A) and does not state any purchases or sales. The filing lists voting and dispositive powers but does not describe transactional intent or timing.
What share count was used to calculate the 7.63% ownership percentage?
The percentage is calculated using 25,803,199 shares outstanding as reported in the Preliminary Proxy Statement on Schedule 14A, referenced for the March 25, 2026 share total.
Do Empery Funds or Mr. Lane claim direct beneficial ownership of each other’s shares?
No. The filing states the Investment Manager and Mr. Lane may be deemed to beneficially own shares held by the Empery Funds due to managerial roles, but each Reporting Person disclaims beneficial ownership of shares owned by another.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Precision BioSciences, Inc.
(Name of Issuer)
Common Stock, $0.000005 par value per share
(Title of Class of Securities)
74019P207
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
74019P207
1
Names of Reporting Persons
Empery Asset Management, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,968,879.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,968,879.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,968,879.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.63 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
74019P207
1
Names of Reporting Persons
Ryan M. Lane
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,968,879.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,968,879.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,968,879.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.63 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Precision BioSciences, Inc.
(b)
Address of issuer's principal executive offices:
302 East Pettigrew Street, Suite A-100, Durham, NC 27701
Item 2.
(a)
Name of person filing:
This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to Common Stock, par value $0.000005 per share (the "Common Stock") of Precision BioSciences, Inc., a Delaware corporation (the "Company"):
(i) Empery Asset Management, LP (the "Investment Manager"), with respect to the Common Stock held by funds to which the Investment Manager serves as investment manager (the "Empery Funds"); and
(ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the Common Stock held by the Empery Funds.
The Investment Manager serves as the investment manager to each of the Empery Funds. Mr. Lane (the "Reporting Individual") is the managing member of a limited liability company that is the managing member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is:
1 Rockefeller Plaza, Suite 1205
New York, New York 10020
(c)
Citizenship:
Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
(d)
Title of class of securities:
Common Stock, $0.000005 par value per share
(e)
CUSIP No.:
74019P207
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 25,803,199 shares of Common Stock outstanding as of March 25, 2026, as reported in the Company's Preliminary Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 27, 2026.
The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all of the Common Stock held by the Empery Funds. The Reporting Individual, as the managing member of the limited liability company that is the managing member of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all of the Common Stock held by the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individual hereby disclaims any beneficial ownership of any such Common Stock.
(b)
Percent of class:
7.63 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a) above.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
